Six-amino acid HGF (hepatocyte growth factor) mimetic. Crosses BBB orally; promotes synaptogenesis in animal models.
Evidence is experimental. Most claims trace to limited human studies or animal models. Treat as a research direction, not a protocol.
Washington State University (Harding lab) candidate. Preclinical models show ~7-orders-of-magnitude greater potency than BDNF for synaptogenesis. Patented; M3 Biotechnology / Athira Pharma developed related candidates. No published human trials of DIHEXA itself.
No human safety data. Strong synaptogenic effect in rodents could plausibly drive un-modeled CNS adverse effects in humans. Identity verification poor.
norLeu-Tyr-Ile-(6)-amido-hexanoic acid. Modified scaffold.
Stack doesn't rank peptides — we surface the diversity of opinion. Each card paraphrases a public-record stance from a named source. Where they conflict is where you should slow down and read both.
Harding lab developed Dihexa as an angiotensin-IV-derivative analog for cognitive disorders. Pre-clinical data shows synaptogenic activity ~7 orders of magnitude greater than BDNF in vitro. The lab has published primarily on rodent models; human clinical trials are absent.
No human Phase 2/3 trials registered. The synaptogenic-magnitude claim is from in-vitro data and has not been translated to clinical outcomes. PCAC review scheduled February 2027 — until then, Dihexa is research-grey only.
Per-claim grading. Each claim is graded independently — same peptide, different claims can carry different grades.
External links to PubMed searches, ClinicalTrials.gov, and FDA materials. We do not host papers — we point at canonical sources.
Pre-filled with this compound's published dose range: 8-45 mg · daily, oral
Draw volume exceeds 100 units (1 mL). Either reduce dose or split into multiple injections.
Calculator is a discussion tool. Verify reconstitution + dosing with a qualified provider. Stack is not a prescription source. Use sterile technique and inspect every vial.
FDA Cat. 2 removed Apr 2026 — PCAC review Feb 2027
FDA's Pharmacy Compounding Advisory Committee scheduled to review the second cohort of peptides removed from Category 2 in April 2026. Panel votes whether to add each to the official 503A bulks list.
FDA published a Federal Register notice on April 15 2026 removing 12 peptides from the Category 2 ('significant safety concerns') compounding list, paving the way for PCAC review for inclusion on the 503A bulks list. Peptides removed: BPC-157, TB-500, Epitalon, GHK-Cu (injectable), MOTS-c, DSIP, Dihexa Acetate, MK-677, Melanotan II, KPV, Semax, LL-37.
FDA's Pharmacy Compounding Advisory Committee categorized a wide list of peptides as Category 2 ('significant safety concerns'), effectively banning their compounding at 503A and 503B pharmacies. Affected: BPC-157, TB-500, Epitalon, GHK-Cu, MOTS-c, DSIP, Dihexa, MK-677, Melanotan II, KPV, Semax, Selank, LL-37 and others.